Conversely, C3 DLBCL cases harbored BCL2 mutations, as well as mutations affecting chromatin modifiers (KMT2D, CREBBP, and EZH2), B-cell transcription factors (MEF2B, IRF8), BCR-and PI3K-signaling modifiers (TNFSF14, HCNV1, GNA13), and PTEN-inactivating mutations [20]. The gene discussed is CREBBP; the disease is diffuse large B-cell lymphoma.